MVR-C5252

N/A

Report date: 2026/05/25 20:02:40

Base Information

Drug NameMVR-C5252
Drug Alias NameC-5252MVR-C5252T-5
ClassificationBiologics > Oncolytic virusBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionInterleukin-12 stimulantsAnti-PD-1
TargetsInterleukin-12Programmed cell death protein 1
Therapy Area/IndicationsSolid tumoursBrain NeoplasmsGanglioglioma +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesImmvira Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesImmvira Pharma Co LtdDuke UniversityChina Resources Biopharmaceutical Co Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsSolid tumoursBrain NeoplasmsGanglioglioma +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A